Tuberculous meningitis (TBM) results from dissemination of M. tuberculosis to the cerebrospinal fluid (CSF) and meninges. Ischaemia, hydrocephalus and raised intracranial pressure frequently result, leading to extensive brain injury and neurodisability. The global burden of TBM is unclear and it is likely that many cases are undiagnosed, with many treated cases unreported. Untreated, TBM is uniformly fatal, and even if treated, mortality and morbidity are high. Young age and human immunodeficiency virus (HIV) infection are potent risk factors for TBM, while Bacillus Calmette-Guérin (BCG) vaccination is protective, particularly in young children. Diagnosis of TBM usually relies on characteristic clinical symptoms and signs, together with consistent neuroimaging and CSF parameters. The ability to confirm the TBM diagnosis via CSF isolation of depends on the type of diagnostic tests available. In most M. tuberculosis cases, the diagnosis remains unconfirmed. GeneXpert MTB/RIF and the next generation Xpert Ultra offer improved sensitivity and rapid turnaround times, and while roll-out has scaled up, availability remains limited. Many locations rely only on acid fast bacilli smear, which is insensitive. Treatment regimens for TBM are based on evidence for pulmonary tuberculosis treatment, with little consideration to CSF penetration or mode of drug action required. The World Health Organization recommends a 12-month treatment course, although data on which to base this duration is lacking. beneficial is unclear. Other host-directed therapies show promise but evidence for widespread use is lacking. Finally, the management of TBM within health systems is sub-optimal, with drop-offs at every stage in the care cascade.
Introduction
Tuberculous meningitis (TBM) is an extra-pulmonary form of tuberculosis (TB) characterised by sub-acute or chronic inflammation of the meninges as a result of invasion of the sub-arachnoid space by the bacilli M. tuberculosis. Other forms of central nervous system (CNS) TB such as tuberculoma, cerebral abscess, and spinal TB are not categorised as TBM, even though treatment is similar. TBM most commonly affects young children and individuals with human immunodeficiency virus (HIV). In the absence of TB treatment, TBM is uniformly fatal 1 and even with treatment, outcomes are poor and chronic neurodisability is common. Much of the damage caused by TBM is due to host-derived inflammatory responses, yet our understanding of these processes is limited. In this review we describe the current global situation for TBM in terms of our understanding of the pathogenesis and natural history, epidemiology, diagnosis, and treatment. We also explore how TBM is managed within health systems. Challenges in the field of TBM are shown in Table 1 .
Pathogenesis
Primary infection occurs via inhalation of M. tuberculosiscontaining aerosolised droplets, followed by activation of neutrophils, dendritic cells and alveolar macrophages, which engulf the mycobacteria in the terminal alveoli. Infected cells then migrate to lymphoid tissue, resulting in activation of Th1 cells and production of pro-inflammatory cytokines, with resultant inflammatory changes in the lung parenchyma and vasculature 2 . If the mycobacteria reach the vasculature, haematogenous dissemination can occur, with the potential to invade the CNS [3] [4] [5] .
The pathogenesis of TBM continues to be debated. A key virulence feature of mycobacteria is the ability to invade the blood-brain and blood-cerebrospinal fluid (CSF) barriers. The invasion mechanisms are not clear, although in vitro and animal data suggest that M. tuberculosis may rearrange the actin of the layers 4, 6 . It is also possible that a "Trojan horse" mechanism, by which M. tuberculosis is brought across the blood-brain barrier by infected macrophages and neutrophils, may occur 7 . Rich and McCordock described the development of a caseating "Rich" focus in the context of TBM pathogenesis 8, 9 . It is suggested that the Rich focus is formed via activation of microglial cells and astrocytes once the bacilli have gained access to the brain. Once formed, the Rich foci may become activated rapidly or months to years later, resulting in release of 
Natural history
The risk and severity of TBM are altered by the status of the host immune response and pathogen virulence, consistent with the damage response framework 10 . Multiple host factors such as age, HIV co-infection, Bacillus Calmette-Guérin (BCG) immunisation, malnutrition, and helminth co-infection may lead to either a deficient or exaggerated immune response to mycobacterial infection.
Age
Several studies conducted in the pre-chemotherapy era identified children who had been exposed to TB and followed them for tuberculin skin test conversion, chest radiograph changes, clinical progression, and mycobacterial culture positivity. Marais and colleagues reviewed these studies and proposed a timetable for TB, in the absence of drug therapy 11 . Following infection with M. tuberculosis, young children are at high risk of progression to TB disease including disseminated forms such as TBM. Both the risk of disease progression and risk of dissemination fall rapidly through childhood, reaching a nadir in the primary school age. In more recent cohorts of children with TBM, the median age is between two and four years 12 . Marais and colleagues also found that children who develop miliary TB or TBM generally do so from one to four months after exposure.
HIV HIV co-infection is the most significant risk factor for TBM in adults and is believed to attenuate the host immune response in the CSF. The impact of HIV on the clinical presentation of TBM is debated, with some studies suggesting a higher rate of extra-meningeal disease and of TB drug resistance [13] [14] [15] [16] . Other studies report that the clinical course of TBM is unaltered by HIV infection 17, 18 .
BCG, helminth infections and nutrition
Neonatal BCG immunization is effective in preventing childhood TB, particularly TBM and miliary TB [19] [20] [21] . Efficacy varies from as high as 80% near the poles, to <20% near the equator, possibly due to masking or blocking from environmental mycobacteria or modulation due to helminth infections 20, 22, 23 . Helminth infections activate a T helper type 2 and/or regulatory T cell response and may down-regulate T helper type 1 and T helper type 17 responses to mycobacterial antigens, potentially decreasing BCG vaccine immunogenicity. Whether this is clinically important is unclear [24] [25] [26] [27] [28] [29] [30] [31] . Several epidemiological, clinical and laboratory studies have demonstrated that malnutrition, a form of acquired immunodeficiency, increases susceptibility to TB. In particular, vitamin D and vitamin D receptor polymorphisms are critical for function of macrophages in the context of TBM [32] [33] [34] . Vitamin D deficiency was significantly more common in TBM compared to controls and pulmonary TB in an Indian study 35 .
Strain type
There are seven main M. tuberculosis lineages, each associated with varying degrees of proinflammatory host response. The modern lineage x (Beijing) is associated with disseminated extra-pulmonary disease, drug resistance, and possibly poor treatment outcomes [36] [37] [38] [39] . One plausible mechanism of Beijing strain survival is a dampened IFN-γ host inflammatory response, promoting high bacterial load.
Epidemiology
Our understanding of the global burden of TBM is poor. Because of inadequate diagnostic test performance and availability, many cases of TBM remain undiagnosed. Autopsy studies in adults with HIV have found high proportions of TB co-infection, commonly with extrapulmonary disease, including meningitis, which is frequently undiagnosed and untreated prior to death 40 . Even those cases diagnosed may not be appropriately reported as individuals with TBM are usually diagnosed in hospitals, which in some contexts, are less likely to be reporting units for TB 41 .
The proportion of TBM in cohorts of TB varies dramatically by the local TB prevalence, age, HIV prevalence, and whether the cohort is describing all or only hospitalized persons (which tend to have a higher proportion of TBM cases). A population-based estimate in a low TB-prevalence settings suggested that around 1% of TB cases were TBM 42 , while a paediatric hospital-based cohort of confirmed TB in a high TB-burden setting suggested that over 10% of TB cases were TBM 43 . Given that the World Health Organization (WHO) estimates 10.4 million new TB cases each year (of which 1 million are children), we suggest that at least 100,000 individuals develop TBM develop annually, but this figure may be much higher.
Untreated, TBM is uniformly fatal. A study from the pre-chemotherapy literature in children demonstrated that the median time to death was 19 and a half days 44 . Even if treated, up to 20% of children will die and, of survivors, over half have severe neurodevelopmental sequalae 45 . Mortality in HIV-infected adults treated for TBM can be as high as 60% in some cohorts, dependent on degree of immunosuppression, use of antiretroviral therapy and stage of TBM at presentation 14, 46 . The total mortality impact of this condition is unclear, and likely underestimated.
Morbidity in TBM survivors is heavily dependent on the age at which the disease occurs and the context in which the individual is living. Survivors require extensive support from medical staff, physiotherapy, occupational therapy, pharmacists and dieticians. Many of these services are not widely available in high TB-burden settings. They also require vast commitments from family and community members, with implications for their quality of life and economic circumstances. Given that they have more potential life years ahead, children lose more disability adjusted life years than older individuals. Even in children with limited neuromotor disability following treatment, cognitive disability, attention-deficit and behavioural problems are more common with TBM survivors than with community controls 47, 48 .
Diagnostics
TBM remains difficult to diagnose. Clinical features such as fever, headache, neck stiffness, or a 'typical' CSF pattern (elevated protein, lymphocytic pleocytosis, and low glucose) cannot reliably distinguish TBM from other forms of sub-acute meningitis 49, 50 . Neuroimaging is frequently unavailable in high TB burden contexts. Where characteristics features of TBM are present on neuroimaging, combinations of basal enhancement, tuberculomas, infarction or hydrocephalus support (but do not confirm) the diagnosis. Many cases of TBM, however, are associated with neuroimaging that does not assist with the diagnosis. Traditional tests to detect bacilli include acid fast bacilli (AFB) smear and culture. AFB smear is rapid and widely available but only 10-15% sensitive in most settings 49, 51 . Culture is more sensitive (~50-60%) but results return too slowly to allow for clinical intervention (two-six weeks depending on the media) [50] [51] [52] [53] . Death frequently occurs prior to culture results if empiric therapy has not been initiated in the interim period 50 . Culture also requires a biosafety level three laboratory, limiting use to referral centres in many settings.
In recent years, nucleic acid amplification tests (NAATs) have been utilised for TBM diagnosis. The most notable tests are GeneXpert MTB/RIF (Xpert) and the re-engineered GeneXpert MTB/RIF Ultra (Xpert Ultra), though other commercial and 'in-house' NAATs have been used as well 54 . Xpert and Xpert Ultra (Cepheid, Inc, Sunnyvale, CA, USA) are cartridge-based, rapid, fully automated polymerase chain reaction (PCR) tests. In 2013, the WHO recommended Xpert as the initial test for diagnosis of TBM based on a systematic review of 13 studies [55] [56] [57] . Sensitivity is generally similar to culture (50-60%), but with a run-time of two hours 51, 53, 58 . Xpert and culture frequently detect cases that the other modality misses and Xpert's negative predictive value is only 84-94%, meaning that while Xpert is helpful if positive, it cannot effectively rule out TBM 51, 59, 60 . One way to maximise Xpert's utility is to centrifuge larger volumes of CSF (>5ml), although this effect has not been universally observed 51 . At present, access to Xpert is increasing although still not adequate 61 .
Xpert Ultra utilizes the same instrument as Xpert with a software upgrade. WHO has recommended Xpert Ultra in place of Xpert for TB meningitis based on one study of Ugandan HIV-infected adults with suspected TBM, which found 95% sensitivity versus a composite microbiological end point, and 70% sensitivity versus consensus research case definitions 52, 62 . This was as opposed to inferior sensitivities for both Xpert and culture versus the same reference standards 52, 63 . A recent cohort reported 86% sensitivity for Xpert Ultra for definite TBM versus 36% for Xpert and 14% for culture 64 .
Negative predictive values remain inadequate to 'rule-out' TBM and the publication of additional studies of Xpert Ultra is required to fully evaluate this technology.
Although there is hope that immunodiagnostics will bridge the gap from Ultra to a definitive diagnostic tool-kit for TBM, thus far, adenosine deaminase, INF-γ release assays, and antibody tests, among others, have not yet proven adequate adjunctive tests for TBM 54, 65 . Thus, diagnostic tests remain imperfect (though improving) and a low threshold to start empiric therapy remains a key to effective management of TB meningitis.
Treatment
The evidence to guide treatment in TBM is limited, based mainly on experience with pulmonary TB 66 . The first treatment option for TBM, streptomycin became available in 1946 67, 68 , albeit at the cost of long, painful treatment duration and poor survival [69] [70] [71] [72] [73] [74] [75] . Para-amino salicylic acid (PAS), introduced in the early 1950s, given in combination with streptomycin reduced resistance and mortality, even with poor CSF penetration 72, [76] [77] [78] [79] . Isoniazid, with low toxicity and better CNS penetration, was introduced in 1952, whereafter outcomes improved 76, 77, [80] [81] [82] [83] . Rifampicin and pyrazinamide were used in TBM treatment regimens from 1970 onwards; however, initially there was no significant reduction in mortality compared to regimens containing streptomycin, PAS and isoniazid 76, [84] [85] [86] [87] . Available treatment options for TBM are hampered by poor CSF penetration and toxicity 76, 88 . Of the first-line TB drugs, pharmacokinetic studies have shown that isoniazid and pyrazinamide have the best CSF penetration 88 . In children, modelling suggests that higher dosages of rifampicin may be required 89 , while in adults, doses up to 600mg per day increases CSF penetration 88, 90 . Ethambutol and streptomycin both have poor CSF penetration. Second-line TB drugs with good CSF penetration include ethionamide, the fluoroquinolones (levofloxacin, moxifloxacin and ofloxacin) and terizidone 88 . Linezolid is another potential treatment option, given excellent CSF penetration 76, 91 . Moxifloxacin up to 800mg per day has demonstrated good CSF concentration with low toxicity 90, 92 . Current WHO treatment guidelines for TBM recommend two months of a four-drug regimen (rifampicin, isoniazid, pyrazinamide and ethambutol) in both adults and children, followed by 7-10 months of rifampicin and isoniazid 93, 94 . Similar dosing to pulmonary TB is advocated based on low quality evidence (Table 2) 88,95
. Thus, the focus of recent TBM trials has been to optimize CNS penetration while minimizing toxicity using alternative regimens, higher doses and/or shorter treatment. Adjunctive levofloxacin (20mg/kg per day) did not demonstrate increased survival benefit among adults in one Vietnamese randomized controlled trial [96] [97] [98] . Regarding dosing strategies, high-dose intravenous rifampicin for the first two weeks of treatment demonstrated increased CSF drug concentration as well as significant reduction in six-month mortality 90, 99, 100 . Similarly, a study evaluating an abbreviated course (six months in HIV-uninfected and nine months in HIV-infected children) of a high dose four-drug regimen (rifampicin 20mg/kg, isoniazid 20mg/kg, pyrazinamide 40mg/kg and ethionamide 20mg/kg) demonstrated mortality of less than 5%
101
. Adjuvant immunomodulatory treatment is used in TBM to ameliorate the potentially damaging host response. A 2016 Cochrane systematic review and meta-analysis found that adjunctive corticosteroids reduce mortality in the short term but had no effect on long-term neurological disability in HIV-uninfected patients with TBM; however, the benefit of corticosteroids is unclear in HIV co-infected individuals 102 . Corticosteroids may have a differential effect dependent on leukotriene A4 hydrolase genotype, being beneficial in those with a hyper-inflammatory genotype but detrimental in others. Use of adjunctive aspirin has been shown to be beneficial in adults with TBM 103, 104 , with one recent study of high dose aspirin demonstrating prevention of new cerebral infarction in adults 105 . This effect, however, has not been demonstrated in children and requires larger randomised trials in adults 106 . Currently registered clinical trials for TBM are shown in Table 3. TB mass lesions, usually in the setting of immune reconstitution inflammatory syndrome (IRIS) and optochisamic arachnoiditis, are difficult to treat and often occur near vital structures in the brainstem and spinal cord. Thalidomide, a potent TNF-α inhibitor, has demonstrated clinical benefit in both TB mass lesions and optochiasmic arachnoiditis 107, 108 . Reports have also demonstrated a clinical role for other agents that cause TNF-α inhibition, including infliximab and IFN-γ [109] [110] [111] . Prophylactic pyridoxine (5-10 mg per day in children and 10 mg per day in adults) is recommended to prevent isoniazid related peripheral neuropathy 93, 94 . Neuropathy is more severe during pregnancy, HIV co-infection, alcohol dependency, malnutrition, diabetes, chronic liver disease and renal failure. Treatment of hydrocephalus depends on the level of CSF obstruction. Communicating hydrocephalus, a common complication of TBM, can be successfully treated with one month of acetazolamide 50 mg/kg per day and frusemide 1 mg/kg per day 112, 113 .
Health systems
The care cascade for TBM has not been specifically investigated. For TB more generally, large gaps exist at every stage from incidence to diagnosis, from diagnosis to treatment and from treatment initiation to favourable outcome [114] [115] [116] . However, there are specific challenges for health systems in their management of TBM, including rehabilitation following treatment conclusion, that suggest gaps could be even larger than for TB as a whole.
Symptoms of TBM are non-specific and community sensitisation is poor. Even where sensitisation to TB has occurred, this is usually to the symptoms and signs of pulmonary TB, such as cough, weight loss, night sweats and haemoptysis 117 . If individuals with TBM do present for evaluation, it is commonly to primary care facilities, at which staff training and experience can be limited and appropriate investigations, such as lumbar puncture or cerebral imaging, are often unavailable. Multiple presentations to healthcare workers are common and are associated with delayed diagnosis and treatment initiation 118, 119 . Referral from primary care to hospital can lead to further delays and frequently incur costs to patients and families. These delays can lead to clinical deterioration 120 .
Even when an individual presents to a hospital for evaluation, the availability of Xpert is variable globally 61 . Although AFB smear is widely available, it has limited sensitivity and culture, if available, returns results in a timescale that is not clinically useful. Although drug therapy is usually provided freely by national TB programmes and is available at peripheral care settings, the specialist services required to appropriately manage TBM, such as paediatrics, neurology, neurosurgery and rehabilitation, are usually only available in specialist centres in larger urban areas and frequently incur costs for patients.
Surveillance data for TBM is limited, with cases rarely reported if patients die before starting treatment. Many patients with TBM are cared for in hospitals for most of their illness and given that many hospitals are not TB-reporting units, these cases are not reflected in regional, national or global reports. Disaggregation of data occurs to the level of pulmonary TB and extrapulmonary TB, without specifying the site of disease. Some electronic registers allow the recording of International Classification of Diseases 10 th revision (ICD-10) codes, but these are often poorly completed.
Conclusions
TBM is the most severe form of TB and is associated with high mortality and morbidity. Our understanding of the global burden is limited but it is likely that most cases are not diagnosed and appropriately treated. At least 100,000 cases are likely to occur each year. The current diagnostic tools are largely inadequate, and treatment is usually started only once substantial neurological damage has occurred. Treatment, both anti-mycobacterial and anti-inflammatory, require further investigation and optimisation, and improvements at every stage along the care cascade are urgently needed.
Data availability
No data are associated with this article.
report of its use in a one-year-old infant. Yale J Biol Med. 1946; 18: 221-226. actually available and the barriers to implementation of such testing at the healthcare system level in those where the testing does not exist.
The treatment discussion is nicely delineated, with a historical and current perspective discussion. Missing from the discussion is commentary on treatment in the pediatric population and treatment initiation of antiretroviral medications in patients with TBM, both challenges to those at the bedside treating such patients. It would be worthwhile to expand the treatment section to include supportive care given the importance of neurointensive care efforts including ICP monitoring, treatment of hyponatremia, when to consider shunting etc.
The healthcare systems section of the paper is important and novel and would benefit perhaps from a visual of the current system at the primary, secondary and tertiary care health systems levels and major knowledge gaps/policy gaps in clinical practice. Table one is also important in terms of future directions beyond implications of challenges in TBM--how do we study and fill this knowledge gap is essential in TBM.
Expansion of
Overall, while the article does not provide new data on TBM, the review provides an important summary on our current state of knowledge, with an emphasis on knowledge gaps. I applaud the authors for their work on this important disease, and look forward to further fruitful work from the consortium. 
